Opposing effects of reduced kidney mass on liver and skeletal muscle insulin sensitivity in obese mice

Siew Hung Chin\textsuperscript{1,2,3}, Flurin Item\textsuperscript{1,2}, Stephan Wueest\textsuperscript{1,2}, Zhou Zhou\textsuperscript{4}, Michael S. F. Wiedemann\textsuperscript{1,2,3}, Zhibo Gai\textsuperscript{6}, Eugen J. Schoenle\textsuperscript{1,2}, Gerd A. Kullak-Ublick\textsuperscript{6}, Hadi Al-Hasani\textsuperscript{4,5}, Daniel Konrad\textsuperscript{1,2,3}

\textsuperscript{1}Division of Pediatric Endocrinology and Diabetology and \textsuperscript{2}Children’s Research Centre, University Children’s Hospital, CH-8032 Zurich, Switzerland

\textsuperscript{3}Zurich Centre for Integrative Human Physiology, University of Zurich, CH-8057 Zurich, Switzerland

\textsuperscript{4}German Diabetes Center at Heinrich Heine University and \textsuperscript{5}German Center for Diabetes Research, D-40225 Düsseldorf, Germany

\textsuperscript{6}Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, CH-8091 Zurich, Switzerland

Correspondence to:
Daniel Konrad, MD PhD
University Children’s Hospital
Department of Endocrinology and Diabetology
Steinwiesstrasse 75
CH-8032 Zurich
Tel: ++41-44-266 7966; Fax: ++41-44-266 7983
Email: daniel.konrad@kispi.uzh.ch
Abstract

Reduced kidney mass and/or function may result in multiple metabolic derangements, including insulin resistance. However, underlying mechanisms are poorly understood. Herein, we aimed to determine the impact of reduced kidney mass on glucose metabolism in lean and obese mice. To that end, seven-week-old C57BL6/J mice underwent uninephrectomy (UniNx) or sham operation. After surgery, animals were fed either a chow (standard) or a high fat diet (HFD) and glucose homeostasis was assessed 20 weeks after surgery. Intraperitoneal glucose tolerance was similar in sham-operated and UniNx mice. However, insulin-stimulated glucose disposal in vivo was significantly diminished in UniNx mice, whereas insulin-stimulated glucose uptake into isolated skeletal muscle was similar in sham-operated and UniNx mice. Of note, capillary density was significantly reduced in skeletal muscle of HFD-fed UniNx mice. In contrast, hepatic insulin sensitivity was improved in UniNx mice. Furthermore, adipose tissue HIF1α-expression and inflammation was reduced in HFD-fed UniNx mice. Treatment with the angiotensin II receptor blocker telmisartan improved glucose tolerance and hepatic insulin sensitivity in HFD-fed sham-operated but not UniNx mice. In conclusion, UniNx protects from obesity-induced adipose tissue inflammation and hepatic insulin resistance but it reduces muscle capillary density and, thus, deteriorates HFD-induced skeletal muscle glucose disposal.
Introduction

Metabolic disorders such as obesity, diabetes, and dyslipidemia may lead to progressive renal damage. Conversely, there is increasing evidence that reduced kidney function may deteriorate glucose metabolism and insulin sensitivity in humans (1; 2). In addition, live kidney donation may increase the risk to develop insulin resistance and the metabolic syndrome (3; 4). Such clinical observation is supported by recent experimental studies in rats showing the development of glucose intolerance, dyslipidemia, and ectopic fat accumulation in parallel with the development of uremia in uninephrectomized animals (5; 6). Mechanistically, overnutrition may activate the renin angiotensin system (RAS) and, thus, may contribute to the pathogenesis of the metabolic syndrome in the presence of reduced renal function. In particular, activation of the RAS/angiotensin receptors (ATRs) impairs insulin signaling in adipose tissue, skeletal muscle and liver (7) and its prevention by ATR blockade (pharmacologically or genetically) improves glucose homeostasis (8; 9). In particular, the angiotensin II type 1 receptor blocker telmisartan was previously reported to improve obesity-/HFD-associated adipose tissue inflammation (10-12). Moreover, uninephrectomized rats developed fat redistribution that could be prevented by treatment with an angiotensin-converting enzyme (ACE)-inhibitor (6).

Skeletal muscle is the major site of insulin-induced glucose disposal in the postprandial state. Besides directly stimulating glucose uptake into muscle fibers, insulin increases microvascular blood flow to the muscle accounting for approximately half of the insulin-mediated glucose uptake (13). Accordingly, the number of capillaries perfusing the muscle is positively related to peripheral insulin action (14). Moreover, reduced blood flow to the muscle is correlated with insulin resistance (15-18) and
insulin-resistant humans and rodents exhibit capillary rarefaction (19-21). However, it still remains unclear whether the reduction in capillaries is a cause or consequence of muscle insulin resistance (22).

In the present study, we sought to determine the impact of reduced kidney mass as established by uninephrectomy (UniNx) on glucose metabolism in HFD-fed mice. Unexpectedly, we found that UniNx resulted in decreased adipose tissue inflammation and improved hepatic insulin sensitivity and steatosis. In contrast, UniNx reduced skeletal muscle capillary density and deteriorated muscle insulin action \textit{in vivo}. 
Research Design and Methods

Animals

Male C57BL/6J (C57BL/6JOLA-Hsd)-mice were purchased from Harlan (AD Horst, The Netherlands). All mice were housed in a specific pathogen-free environment on a 12-hour light-dark cycle (light on from 7 pm to 7 am) and fed ad libitum with regular chow diet (Provimi Kliba, Kaiseraugst, Switzerland) or high fat diet (HFD) (58 kcal% fat w/sucrose Surwit Diet, D12331, Research Diets). All protocols conformed to the Swiss animal protection laws and were approved by the Cantonal Veterinary Office in Zurich, Switzerland.

Surgical procedures

Male C57BL/6J mice underwent uninephrectomy or sham operation at seven weeks of age. Mice were anesthetized with isoflurane (Abbott, Baar, Switzerland). Mice were placed on a warming-pad and kept under an infrared heating lamp to stabilize body temperature during the whole surgical procedure. Left nephrectomy was performed through a 1.0 cm incision on left dorsolateral paralumbar region as follows. After skin incision, abdominal muscles were incised to expose retroperitoneal region. Left kidney was secured with a clamp (FRANCIS chalazion forceps, D-8425) and fat attached to kidney was removed. Special care was taken to prevent damage to the adrenal gland. Renal blood vessels and ureter were ligated with sterile silk surgical sutures. Subsequently, left kidney was excised distal to ligatures. Abdominal muscles were sewn with reabsorbal thread and opposite ends of incised skin was clipped together using sterile disposable skin staplers. Sham-operated control mice underwent identical
surgical procedure except for kidney removal. Subcutaneous injection of buprenorphine (Essex, Luzern, Switzerland) every 6 hours for 2 days was used for analgesia.

**Intra-peritoneal glucose and insulin tolerance tests**

For intraperitoneal glucose tolerance test (ipGTT) mice were fasted overnight and for intraperitoneal insulin tolerance tests (ipITT) for 3h. Either glucose (2 g/kg body weight) or human recombinant insulin (1.0 U/kg body weight) were injected intraperitoneally (23).

**Glucose clamp studies**

Glucose clamp studies were performed as described (24). Clamps were performed in freely moving mice. Glucose infusion rate was calculated once glucose infusion reached a more or less constant rate with blood glucose levels at 5 mmol/l (80–90 min after the start of insulin infusion). Thereafter, blood glucose was kept constant at 5 mmol/l for 20 min and glucose infusion rate was calculated. The glucose disposal rate was calculated by dividing the rate of $[3^{-3}\text{H}]$glucose infusion by the plasma $[3^{-3}\text{H}]$glucose specific activity (25). Endogenous glucose production during the clamp was calculated by subtracting the glucose infusion rate from the glucose disposal rate (25; 26). Insulin-stimulated glucose disposal rate was calculated by subtracting basal endogenous glucose production (equal to basal glucose disposal rate) from glucose disposal rate during the clamp (27). In order to assess tissue specific glucose uptake, a bolus (10 µCi) of $2-[1^{-14}\text{C}]$deoxyglucose was administered via catheter at the end of the steady state period. Blood was sampled 2, 15, 25 and 35 min after bolus delivery. Area under the curve of disappearing plasma $2-[1^{-14}\text{C}]$deoxyglucose was used together with tissue-
concentration of phosphorylated 2-[^14]C]deoxyglucose to calculate glucose uptake, as was previously described (28).

**Metabolic cage analysis**

Locomotion, food intake, O$_2$ consumption and CO$_2$ production were determined for single housed mice during a 24-h period in a metabolic and behavioral monitoring system (PhenoMaster, TSE Systems, Bad Homburg, Germany) as described (29).

**Determination of insulin, free fatty acid, angiotensin I, creatinine, uric acid and bile acid levels**

Plasma insulin and free fatty acid levels were determined as described (23). Plasma angiotensin I levels were determined by an ELISA kit (Cusabio Biotech CO Ltd, Wuhan, PR China). Serum creatinine levels were measured using DetectX® Low Sample Volume Serum Creatinine Kit (K0021-H1D, Arbor Assays, Ann Arbor, MI, USA), serum uric acid levels by QuantiChrom™ Uric Acid Assay Kit (DIUA-250, BioAssay Systems, Hayward, CA, USA) and plasma bile acid levels using Mouse Total Bile Acids Assay Kit (80470, Crystal Chem Inc, Downers Grove, IL, USA).

**Glucose incorporation into isolated soleus and EDL muscle**

Mice were fasted for 4 h prior to the analysis. EDL and soleus muscles were removed from anesthetized mice (Avertin, 99% 2,2,2-tribromo ethanol, and tertiary amyl alcohol at 15–17 µl/g body weight ip) and incubated for 30 min at 30°C in vials containing preoxygenated (95% O$_2$-5% CO$_2$) Krebs-Henseleit buffer (KHB) containing 5 mM HEPES (prebuffer) and supplemented with 15 mM mannitol and 5 mM glucose.
Muscles were transferred to new vials containing fresh pre-gassed KHB, as described above with or without 120nM of insulin (Actrapid; Novo Nordisk, Mainz, HE, Germany). Afterwards, muscles were transferred to new vials containing preoxygenized KHB supplemented with 20 mM mannitol and incubated for 10 min. Muscles were then transferred to new vials containing preoxygenized KHB supplemented with 1 mM [\textsuperscript{3}H]2-deoxy-glucose (2.5 µCi/ml), and 19mM [\textsuperscript{14}C]mannitol to account for extracellular space, and incubated for 20 min. After the last incubation, muscles were washed in ice-cold KHB, dried externally on filter paper, and quickly frozen with aluminum tongs precooled in liquid nitrogen and stored at -80°C. Glucose transport rates were determined by scintillation counting of cleared protein lysates as described (30).

**Insulin signaling in skeletal muscle ex vivo**

For assessing insulin-stimulated Akt phosphorylation in skeletal muscle, insulin (2U/kg) was injected i.p. in mice fasted for 5 hours. Skeletal muscles (quadriceps) were harvested 15 minutes after insulin injection, snap frozen in liquid nitrogen and stored at -80°C until homogenization.

**Histology**

Fat tissues were fixed in 4% buffered formalin and embedded in paraffin. Sections were cut and stained with hematoxylin and eosin. For each fat pad at least 100 adipocytes were analyzed. Quadriceps femoris muscle was mounted in embedding medium (o.c.t. embedding matrix, CellPath Ltd., Newtown, UK), snap frozen in isopentane cooled to -160°C with liquid nitrogen, and subsequently stored at -80°C until use. Consecutive 12 µm sections were cut on a microtome at -25°C. Rat anti-mouse
CD31 endothelial cell antibody (BioLegend, San Diego, CA) was used as a marker for muscle capillaries, and capillary-to-fiber ratio was calculated by dividing the number of CD31-positive cells by the number of muscle fibers. For all histochemical and immunohistochemical analyses NIH Image J software (National Institutes of Health, Bethesda, MD) was used.

*Total liver lipid and triglyceride determination*

Liver tissue (10-30mg) was homogenized in PBS and lipids were extracted in a chloroform-methanol (2:1) mixture. Total liver lipids were determined by a sulfophosphovanillin reaction as previously described (31). Liver triglycerides were measured from 50 mg of liver tissue using a variation of the Bligh and Dyer method (32) and quantified with an enzymatic assay (Roche Diagnostics, Rotkreuz, Switzerland).

*RNA extraction and quantitative reverse transcription-PCR (RT-PCR).*

Total RNA was extracted and reverse transcribed as described (33). The following primers were used: TNF-α Mm00443258_m1, IL-6 Mm00446190_m1, IL-1β Mm0043422/8_m1, cd11c Mm00498698_m1, ATGL Mm00503040_m1, perilipin Mm00558672_m1, HIF1α Mm00468869_m1, CD31 Mm01242584_m1, VEGF-A Mm01281441_m1 (Applied Biosystems, Rotkreuz, Switzerland).

*Western Blotting*

Cells or tissues were lysed and Western blots were performed as previously described (33). The following primary antibodies were used: anti-phospho-Akt (Ser473),
anti-total Akt (Cell Signaling, Danvers, MA, USA), anti-VEGF-A (Santa Cruz Biotechnology Inc., Dallas, TX, USA) and anti-actin (Millipore, Zug, Switzerland).

Data analysis

Data are presented as mean +/- SEM and were analyzed by unpaired Student’s t test. p-Values < 0.05 were considered significant.
Results

*Improved hepatic but deteriorated muscle insulin sensitivity in HFD-fed UniNx mice*

Surgical procedure (sham operation or UniNx) was performed in C57BL6/J mice at seven weeks of age. Mice were fed either normal chow or HFD for 20 weeks. Total body weight gain was similar in sham-operated and UniNx mice under both diets (Table 1). After 20 weeks of HFD, inguinal and mesenteric fat pad weights in the UniNx mice were comparable to sham-operated mice, whereas epididymal fat pad weight was significantly higher in UniNx mice (Table 1). No differences in fat pad weights were observed between chow-fed sham-operated and UniNx mice (Table 1). In addition, food intake, locomotion, or fuel utilization (respiratory quotient, RQ) was similar between HFD-fed sham-operated and UniNx mice (Supplementary Figure 1).

Fasting blood glucose levels were similar between HFD-fed sham-operated and UniNx mice (Table 2). In addition, plasma insulin and free fatty acid (FFA) concentrations did not differ significantly between both groups (Table 2). Glucose and insulin tolerance were similar in UniNx mice compared to sham-operated mice under both standard chow as well as HFD 20 weeks after surgery (Figures 1A and 1B). Hyperinsulinemic-euglycemic clamp studies revealed similar glucose infusion rate in HFD-fed UniNx compared to sham-operated mice (see Figure 1C for steady-state glucose infusion rates and Supplementary Figure 2 for detailed time courses). Importantly, insulin-induced suppression of endogenous glucose production (mainly reflecting hepatic glucose production) was blunted in HFD-fed sham-operated mice, but was clearly evident in UniNx mice (Figure 1D) indicating improved/preserved hepatic insulin sensitivity in the latter. In contrast, glucose disposal rate during hyperinsulinemic-
euglycemic clamp was significantly further deteriorated in HFD-fed UniNx mice suggesting reduced skeletal muscle insulin sensitivity compared to sham-operated mice (Figure 1E).

*Improved hepatic steatosis in HFD-fed UniNx mice*

Hepatic insulin sensitivity is often associated with hepatic steatosis, though it is still debated whether insulin resistance is the cause of hepatic steatosis, or whether the increase in triglycerides (or of lipid metabolites such as ceramides, diacylglycerol and acyl-CoAs) causes the development of hepatic and/or systemic insulin resistance. As depicted in Figure 2A, total liver lipid content was greatly reduced in HFD-fed UniNx compared to sham-operated mice. Similarly, liver triglyceride levels were reduced in HFD-fed UniNx mice (UniNx mice: 234.5 ± 41.0 µmol/g liver; sham-operated mice: 401.3 ± 77.5 µmol/g liver). In addition, histological examination of liver sections revealed reduced frequency of lipid vacuoles in HFD-fed UniNx mice (Figure 2B).

*Reduced adipose tissue inflammation in HFD-fed UniNx mice*

The ‘portal theory’ proposes that the direct exposure of the liver to increasing amounts of FFA and/or pro-inflammatory factors released from visceral fat into the portal vein may promote the development of hepatic insulin resistance and steatosis (34). Accordingly, mRNA expression of pro-inflammatory cytokines as well as adipose tissue histology was analyzed in order to characterize adipose tissue inflammation. As depicted in Figure 2C, expression of CD11c (a marker for pro-inflammatory M1 polarized macrophages) and interleukin-6 (IL-6) was significantly decreased and expression of tumor-necrosis factor alpha (TNFα) and interleukin-1 beta (IL-1β) trendwise reduced in
mesenteric adipose tissue of HFD-fed UniNx compared to sham-operated mice. Of note, 
mRNA levels of the hypoxia-inducible factor 1α (HIF1α) was significantly lower in 
mesenteric adipose tissue of HFD-fed UniNx mice (Figure 2C). In contrast, adipocyte 
size was not different between both groups of mice (Figures 2D and 2E). In addition, 
insulin-stimulated Akt-phosphorylation in adipose tissue was similar in both groups 
suggesting similar insulin sensitivity in this tissue (Figure 2F). Thus, uninephrectomy 
protects mice from the development of HFD-induced adipose tissue inflammation and 
consequently hepatic insulin resistance.

Similar skeletal muscle insulin action in vitro

Glucose uptake into isolated soleus (slow-twitch) and extensor digitorum longus 
(fast-twitch) muscles was assessed next removing extramyocellular barriers to muscle 
glucose uptake. As depicted in Figure 3A and B, basal and insulin-stimulated glucose 
uptake were similar between HFD-fed sham-operated and UniNx mice, suggesting no 
direct impairment of insulin action at the myocyte level. Of note, 20 weeks of HFD led to 
an expected poor insulin response in skeletal muscle, which was particularly evident in 
soleus muscle. Similar to ex vivo glucose uptake, no difference between both groups of 
mice was found for in vivo insulin-stimulated Akt phosphorylation in total muscle 
homogenates (Figure 3C). These data in isolated muscle contrasts the data obtained 
from hyperinsulinemic-euglycemic clamp studies revealing diminished muscle insulin 
sensitivity in HFD-fed UniNx mice and may indicate that UniNx leads to impaired insulin 
delivery to the sarcolemma, e.g. through reduction in capillary density.
Reduced capillary density in skeletal muscle of HFD-fed UniNx mice

In order to assess capillary density, expression of the endothelial marker CD31 was determined. As depicted in Figure 4A, mRNA levels of CD31 were significantly reduced in quadriceps muscle in HFD-fed UniNx compared to sham-operated mice whereas no difference was observed in chow-fed mice (Supplementary Figure 3). Moreover, capillary-to-fiber ratio was significantly (∼15%) reduced in skeletal muscle of HFD-fed UniNx mice (Figures 4B and 4C). Thus, uninephrectomy reduces muscle capillary density in HFD-fed mice. Mechanistically, reduced muscle capillary density may be the result of reduced HIF1α levels, which is a transcriptional activator of genes encoding vascular endothelial growth factor (VEGF) and other important mediators of angiogenesis (35). Indeed, HIF1α and VEGF-A mRNA levels were decreased in skeletal muscle of HFD-fed UniNx mice (Figure 4D). Moreover, protein levels of VEGF-A were decreased by 40% in skeletal muscle of HFD-fed UniNx compared to sham-operated mice (Figure 4E).

Improved hepatic insulin sensitivity in telmisartan-treated HFD-fed sham-operated mice

As reported in Table 2, angiotensin I levels were significantly increased in HFD-fed UniNx mice. Activation of the renin-angiotensin system (RAS) was previously suggested to contribute to HFD-associated skeletal muscle insulin resistance (36-38). Thus, we hypothesized that the observed increase in circulating angiotensin I concentration may deteriorate HFD-induced skeletal muscle insulin resistance via activation of angiotensin II type 1 receptors (AT1R). To test such hypothesis we made use of the AT1R blocker telmisartan. UniNx and sham-operated mice were fed a HFD for 20 weeks and received telmisartan in the drinking water at a dose of 3mg/kg*day during the entire period. As depicted in Figures 5A and 5B telmisartan treatment...
improved glucose tolerance in HFD-fed sham-operated but not UniNx mice. Moreover, it improved glucose infusion rate (Figure 5C) and hepatic insulin sensitivity (Figure 5D) in sham-operated mice as analyzed by hyperinsulinemic-euglycemic clamp studies (see Supplementary Figure 4 for detailed time courses). In accordance with elevated hepatic insulin sensitivity, telmisartan treatment reduced hepatic steatosis in sham-operated mice (total liver lipids in untreated HFD-fed sham-operated mice: 299.4 ± 59.6 mg/g liver tissue; total liver lipids in telmisartan-treated HFD-fed sham-operated mice: 158.0 ± 31.8 mg/g liver tissue) but did not affect it in UniNx mice (total liver lipids in untreated HFD-fed UniNx mice: 123.4 ± 17.7 mg/g liver tissue; total liver lipids in telmisartan-treated HFD-fed UniNx mice: 178.5 ± 22.8 mg/g liver tissue) resulting in similar total liver lipids in telmisartan-treated mice of both groups (Figure 5E). Moreover, mRNA expression levels of pro-inflammatory cytokines in mesenteric adipose tissue were similar between telmisartan-treated HFD-fed sham-operated and UniNx mice (Figure 5F). Of note, expression of HIF1α was no longer different between telmisartan-treated sham-operated and UniNx mice (Figure 5F). Such data suggest that telmisartan treatment improved adipose tissue inflammation in HFD-fed sham-operated mice since the observed difference in cytokine mRNA expression in untreated mice (Figure 2A) was no longer present.

No effect of telmisartan treatment on muscle insulin resistance and capillary rarefaction in HFD-fed UniNx mice

Previously, the angiotensin II receptor blocker losartan was found to reverse insulin resistance through the modulation of muscular circulation in rats with impaired glucose metabolism (20). We therefore postulated that telmisartan would improve
muscle insulin sensitivity as well as capillary density in UniNx mice. However, as depicted in Figure 6A, 20 weeks of telmisartan treatment did not affect insulin-stimulated glucose disposal rate (IS-GDR) in UniNx mice (IS-GDR in untreated HFD-fed UniNx mice: 10.6 ± 1.2 mg/kg*min; IS-GDR in telmisartan-treated HFD-fed UniNx mice: 4.2 ± 2.3 mg/kg*min). Accordingly, insulin stimulated glucose uptake was significantly higher in telmisartan-treated HFD-fed sham-operated compared to UniNx mice (Figure 6B). Moreover, CD31 expression remained reduced in quadriceps muscle of telmisartan-treated HFD-fed UniNx compared to sham-operated mice (Figure 6C). Thus, telmisartan treatment positively impacts on total body and hepatic insulin sensitivity in HFD-fed sham-operated mice but does not affect impaired skeletal muscle insulin sensitivity in HFD-fed UniNx mice.

**Discussion**

In the present study we describe an unexpected dissociation of hepatic and muscle insulin resistance: whereas uninephrectomy protected HFD-fed mice from the development of hepatic insulin resistance (and hepatic steatosis), it deteriorated skeletal muscle insulin resistance.

The observed association of reduced visceral adipose tissue inflammation and improved hepatic insulin sensitivity in HFD-fed UniNx mice is in accordance with the “portal theory” claiming that the exaggerated release of FFAs and/or pro-inflammatory cytokines from visceral fat are directly delivered to the liver via portal vein, promoting the development of hepatic insulin resistance and hepatic steatosis (34). Interestingly, expression of HIF1α was reduced in adipose tissue of UniNx mice. Selective inhibition of
HIF1α was previously reported to reduce adipose tissue inflammation as well as hepatic steatosis in HFD-fed mice (39). Conversely, overexpression of HIF1α induced adipose tissue fibrosis and inflammation as well as hepatic steatosis (40). Thus, uninephrectomy is associated with decreased HIF1α expression in adipose tissue and thereby may contribute to reduced adipose tissue inflammation and, consequently, preserved hepatic insulin sensitivity. Such notion is further supported by the fact that treatment with telmisartan abolished differences in mRNA expression of HIF1α as well as pro-inflammatory cytokines and improved hepatic insulin sensitivity in sham-operated mice.

The kidney contributes to a significant part (~15-20%) to endogenous glucose production in both humans and rats (41; 42). Thus, basal endogenous glucose production may be reduced in UniNx mice. However, similar basal endogenous glucose production was observed in HFD-fed UniNx and sham-operated mice (UniNx: 25.8 mg/kg*min, sham-operated: 22.2 mg/kg*min; p=0.27). Moreover, insulin-mediated suppression of endogenous glucose production was increased in HFD-fed UniNx mice. Since renal glucose production is inhibited by insulin we cannot exclude that such improvement may be due to improved renal insulin sensitivity in UniNx mice. However, the fact that adipose tissue inflammation as well as liver lipid accumulation was decreased in HFD-fed UniNx mice and the notion that endogenous glucose production mainly reflects hepatic glucose production renders improved hepatic insulin sensitivity a more likely explanation herein.

Decreased mRNA expression and histological staining of CD31 point towards reduced capillary density in skeletal muscle of HFD-fed UniNx mice. Capillary rarefaction was previously associated with insulin resistance both in humans and rodents (19-21). In accordance with our findings presented herein, Flisinski et al reported reduced numbers of capillaries as well as a decreased capillary-to-fiber ratio in gastrocnemius and longissimus muscle in UniNx male Wistar rats (43). Such changes were already
present at an early stage and independent of blood pressure. Of note, treatment with the angiotensin II receptor blocker telmisartan had no impact on capillary density in UniNx mice suggesting that UniNx-associated capillary rarefaction is not dependent on activation of the RAS whereas it may modulate muscular circulation and thereby insulin sensitivity as was previously reported for the angiotensin II receptor blocker losartan in rats (20). Herein, reduced capillary density was associated with decreased HIF1α mRNA expression in skeletal muscle of UniNx mice. HIF1α is the master regulator of transcriptional responses to hypoxia and a transcriptional activator of genes encoding vascular endothelial growth factor (VEGF) and other important mediators of angiogenesis (35). Indeed, VEGF-A mRNA and protein levels were reduced in HFD-fed UniNx compared to sham-operated mice suggesting that reduced HIF1α may be responsible for reduced capillary density in the former. Importantly, UniNx and subtotal nephrectomy in Wistar rats were associated with reduced expression of HIF1α, VEGF A and VEGF receptor in gastrocnemius muscle (44). In addition, subtotal nephrectomy reduced skeletal muscle angiogenesis in rats (45). Unfortunately, HIF1α expression was not determined in the latter publication. Moreover, muscle-specific deletion of VEGF resulted in capillary rarefaction and diminished insulin-induced muscle glucose uptake in vivo independent of defects in insulin action at the myocyte (22). Thus, reduced expression of HIF1α may be causally linked to reduced capillary density observed in skeletal muscle of UniNx mice.

In conclusion, UniNx unexpectedly protects mice from HFD-induced adipose tissue inflammation and hepatic insulin resistance potentially via a reduction in HIF1α expression. In contrast, UniNx leads to capillary rarefaction in skeletal muscle and, thus, deteriorates HFD-induced skeletal muscle glucose disposal in vivo.
Acknowledgments

This work was supported by grants from the Swiss National Center for Competence in Research NCCR-Kidney.ch (to GAKU and DK), the Swiss National Science Foundation (#310030-141238) (to DK), the Foundation for Research at the Medical Faculty, University of Zurich (to FI) and the International Fellowship Program (grant no. 246539) on Integrative Kidney Physiology and Pathophysiology (IKPP; to GAKU). MSFW was supported by the Wolfermann-Nägeli-Stiftung. We would like to greatly acknowledge Prof. Giatgen Spinas, University Hospital Zurich, for continuous support, and Dr. Denis Arsenijevic as well as Prof. Jean-Pierre Montani, University of Fribourg, for expert advice regarding the uninephrectomy procedure. Telmisartan was kindly provided by Boehringer Ingelheim International GmbH (MTA 1037).

Author Contributions

DK conceived the study and wrote the paper. SHC, FI, SW, ZZ, MSFW and ZG performed the experimental work. EJS, GAKU and HAH gave conceptual advice. All authors contributed to discussion and reviewed/edited manuscript.

Conflict of interests' statement

All authors state no conflict of interest.
References

15. Chiu JD, Richey JM, Harrison LN, Zuniga E, Kolka CM, Kirkman E, Ellmerer M, Bergman RN: Direct administration of insulin into skeletal muscle reveals that the
transport of insulin across the capillary endothelium limits the time course of insulin to activate glucose disposal. Diabetes 2008;57:828-835


42. Pillot B, Soty M, Gautier-Stean A, Zitoun C, Mithieux G: Protein feeding promotes redistribution of endogenous glucose production to the kidney and potentiates its suppression by insulin. Endocrinology 2009;150:616-624


Figure Legends

**Figure 1** Improved hepatic but deteriorated muscle insulin sensitivity in HFD-fed UniNx mice

Intra-peritoneal glucose (A) and insulin tolerance (B) tests in chow-fed and HFD-fed sham-operated and UniNx mice are shown. Black squares: chow sham-operated (n=7); grey squares: chow UniNx (n=6); black circles: HFD sham-operated (n=15-17); grey circles: HFD UniNx (n=14-17). (C to E) Glucose infusion rate, inhibition of endogenous glucose production and insulin-stimulated glucose disposal rate (IS GDR) during hyperinsulinemic-euglycemic clamps in HFD-fed mice (n=5). Error bars represent SEM. *p < 0.05 and **p < 0.01 (Student’s t-test).

**Figure 2** Reduced hepatic steatosis and adipose tissue inflammation in HFD-fed UniNx mice

(A) Total liver lipids were determined and expressed relative to total liver weight in HFD-fed sham-operated (black bars) and UniNx mice (grey bars). (B) Representative hematoxylin- and eosin-stained histological sections of liver of HFD-fed sham-operated and UniNx mice. Scale bar represents 50 µm. (C) mRNA expression of respective genes in mesenteric adipose tissue of HFD-fed sham-operated (black bars) and UniNx mice (grey bars). n=5-10. *p < 0.05 (Student’s t-test). (D) Representative hematoxylin- and eosin-stained histological sections of epididymal adipose tissue of HFD-fed sham-operated and UniNx mice. Scale bar represents 100 µm. (E) Adipocyte cell perimeter was measured using ImageJ. Up to 100 cells per fat pad of four different mice per group were analyzed. (F) Lysates of white adipose tissue were prepared, resolved by LDS-
PAGE and immunoblotted with anti-pS473 Akt, anti-total Akt or anti-actin antibody. Graphs show results of 4-5 mice. *p < 0.05 (Student’s t-test). All error bars represent SEM.

**Figure 3** Preserved/sustained insulin-stimulated glucose uptake into skeletal muscle *ex vivo*

Glucose uptake into intact isolated soleus muscle (A) and extensor digitorum longus (EDL) muscle (B) was measured in the absence (open bars) or presence of 120 nM insulin (filled bars). n=8. (C) Total muscle lysates were prepared, resolved by LDS-PAGE and immunoblotted with anti-pS473 Akt, anti-total Akt or anti-actin antibody. Graphs show results of 4-5 mice. Error bars represent SEM.

**Figure 4** Reduced capillary density in skeletal muscle of HFD-fed UniNx mice

(A) mRNA expression of CD31 in quadriceps muscle of HFD-fed sham-operated (black bars) and UniNx mice (grey bars). n=4-5. (B and C) CD31 staining of quadriceps muscle harvested from HFD-fed sham-operated and UniNx mice. Capillary-to-fiber ratio was calculated after counting up to 700 fibers and corresponding capillaries per mouse. Scale bar represents 100 µm. n=4. (D) mRNA expression of HIF1α and VEGF-A in quadriceps muscle of HFD-fed sham-operated (black bars) and UniNx mice (grey bars). n=4-5. (E) Total muscle lysates were prepared, resolved by LDS-PAGE and immunoblotted with anti-VEGF-A or anti-actin antibody. Graphs show results of 8 mice. Error bars represent SEM. § p = 0.07, # p = 0.06, *p < 0.05 (Student’s t-test).
Figure 5  Improved hepatic insulin sensitivity in telmisartan-treated HFD-fed sham-operated mice

(A) Intra-peritoneal glucose-tolerance test in telmisartan-treated HFD-fed sham-operated (black circles) and UniNx (grey circles) mice. n=9-11. (B) Analysis of the area under the curve of glucose tolerance tests presented in A. (C) Glucose infusion rate and (D) inhibition of endogenous glucose production during hyperinsulinemic-euglycemic clamps. n=4. (E) Total liver lipids were determined and expressed relative to total liver weight in telmisartan-treated HFD-fed sham-operated (black bars) and UniNx mice (grey bars). n=5-6. All error bars represent SEM. (F) mRNA expression of respective genes in mesenteric adipose tissue of telmisartan-treated HFD-fed sham-operated (black bars) and UniNx mice (grey bars). n=4-5. Error bars represent SEM. *p < 0.05 and **p < 0.01 (Student’s t-test).

Figure 6  No effect of telmisartan treatment on muscle insulin resistance and capillary rarefaction in HFD-fed UniNx mice

(A) Insulin-stimulated glucose disposal rate (IS GDR) and (B) insulin-stimulated glucose uptake into quadriceps muscle during hyperinsulinemic-euglycemic clamps. n=4. (C) mRNA expression of CD31 and HIF1α in quadriceps muscle of HFD-fed telmisartan-treated sham-operated (black bars) and UniNx mice (grey bars). n=4-5. *p < 0.05 and **p < 0.01 (Student’s t-test).
Table 1  Body and organ weight in sham-operated and UniNx mice

<table>
<thead>
<tr>
<th></th>
<th>Sham-operated</th>
<th></th>
<th>UniNx</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Chow</td>
<td>HFD</td>
<td>Chow</td>
<td>HFD</td>
</tr>
<tr>
<td>Body weight (g)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- before surgery</td>
<td>24.5 ± 1.0</td>
<td>25.1 ± 0.6</td>
<td>24.4 ± 0.6</td>
<td>25.1 ± 0.8</td>
</tr>
<tr>
<td>- 20 weeks after</td>
<td>35.2 ± 0.7</td>
<td>51.2 ± 1.0</td>
<td>33.3 ± 0.7</td>
<td>50.4 ± 1.0</td>
</tr>
<tr>
<td>N</td>
<td>7</td>
<td>22</td>
<td>8</td>
<td>22</td>
</tr>
<tr>
<td>Kidney weight (mg)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- right kidney</td>
<td>212 ± 6</td>
<td>231 ± 6</td>
<td>269 ± 7***</td>
<td>284 ± 11***</td>
</tr>
<tr>
<td>- left kidney</td>
<td>203 ± 5</td>
<td>209 ± 6</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>N</td>
<td>7</td>
<td>8</td>
<td>8</td>
<td>7</td>
</tr>
<tr>
<td>Liver weight (mg)</td>
<td>1576 ± 11.7</td>
<td>2458 ± 192***</td>
<td>1454 ± 45</td>
<td>2169 ± 145##</td>
</tr>
<tr>
<td>N</td>
<td>7</td>
<td>13</td>
<td>8</td>
<td>12</td>
</tr>
<tr>
<td>Fat pad weight (mg)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- inguinal</td>
<td>576 ± 74</td>
<td>2479 ± 140###</td>
<td>428 ± 75</td>
<td>2362 ± 97###</td>
</tr>
<tr>
<td>- epididymal</td>
<td>899 ± 97</td>
<td>1857 ± 103###</td>
<td>887 ± 156</td>
<td>2382 ± 150**.###</td>
</tr>
<tr>
<td>- mesenteric</td>
<td>719 ± 158</td>
<td>1416 ± 89###</td>
<td>523 ± 59</td>
<td>1389 ± 131###</td>
</tr>
<tr>
<td>N</td>
<td>7</td>
<td>13</td>
<td>8</td>
<td>12</td>
</tr>
</tbody>
</table>
\*\(p<0.05\), **\(p<0.01\), ***\(p<0.001\) compared to sham-operated mice; \#\(p<0.05\), ##\(p<0.01\), ###\(p<0.001\) compared to chow-fed mice.
Table 2  Circulating blood levels in sham-operated and UniNx mice

<table>
<thead>
<tr>
<th></th>
<th>Sham-operated</th>
<th>UniNx</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Chow</td>
<td>HFD</td>
</tr>
<tr>
<td>Glucose (mmol/l)</td>
<td>7.8 ± 0.7</td>
<td>11.7 ± 0.8##</td>
</tr>
<tr>
<td>N</td>
<td>7</td>
<td>10</td>
</tr>
<tr>
<td>Insulin (ng/ml)</td>
<td>1.6 ± 0.2</td>
<td>7.0 ± 0.6###</td>
</tr>
<tr>
<td>N</td>
<td>7</td>
<td>10</td>
</tr>
<tr>
<td>FFA (mmol/l)</td>
<td>n.d.</td>
<td>0.72 ± 0.9</td>
</tr>
<tr>
<td>N</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Creatinine (mg/dl)</td>
<td>n.d.</td>
<td>0.59 ± 0.03</td>
</tr>
<tr>
<td>N</td>
<td>7</td>
<td>9</td>
</tr>
<tr>
<td>Uric acid (mg/dl)</td>
<td>n.d.</td>
<td>4.4 ± 0.4</td>
</tr>
<tr>
<td>N</td>
<td>8</td>
<td>9</td>
</tr>
<tr>
<td>Angiotensin I (ng/ml)</td>
<td>20.9 ± 2.0</td>
<td>20.6 ± 1.5</td>
</tr>
<tr>
<td>N</td>
<td>6</td>
<td>8</td>
</tr>
<tr>
<td>Bile acids (µmol/l)</td>
<td>8.4 ± 3.1</td>
<td>9.4 ± 1.3</td>
</tr>
<tr>
<td>N</td>
<td>7</td>
<td>10</td>
</tr>
</tbody>
</table>
*p<0.05, **p<0.01, ***p<0.001 compared to sham-operated mice; #p<0.05, ##p<0.01, ###p<0.001 compared to chow-fed mice.
Figure 1

E

**IS GDR (mg/kg*min)**

<table>
<thead>
<tr>
<th></th>
<th>IS GDR (mg/kg*min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham</td>
<td>22</td>
</tr>
<tr>
<td>UniNx</td>
<td>10 **</td>
</tr>
</tbody>
</table>

** indicates a statistically significant difference.
Figure 2

A

Liver lipid content (% total liver weight)

Sham

UniNx

B

Sham

UniNx

C

mRNA expression (relative to 18s) normalized to HFD Sham

Cd11c  IL-6  Tnfα  IL-1β  Hif1α  Cd31  Atgl  Perilipin

*
Figure 3

A

Soleus

Glucose uptake (nmol/mg*min)

Sham
UniNx

B

EDL

Glucose uptake (nmol/mg*min)

Sham
UniNx

C

pS473 Akt

total Akt

Actin

Ins-stimulated pAkt (relative to total Akt)

Sham
UniNx
**Figure 4**

A. **CD31 mRNA expression (relative to 18s), normalized to HFD Sham**

B. **Capillary-to-fiber ratio**

C. **mRNA expression (relative to 18s) normalized to HFD Sham**

D. **Hif1α and Vegf-a mRNA expression (relative to 18s)**
Figure 5

A

Blood glucose (mmol/l)

Time (min)

B

AUC (mmol/l*min)

Sham+T

UniNx+T

C

Glucose infusion rate (mg/kg*min)

Sham+T

UniNx+T

D

Inhibition of endogenous glucose production (%)

Sham+T

UniNx+T
E

Liver lipid content (% total liver weight)

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham+T</td>
<td>20 ± 3</td>
</tr>
<tr>
<td>UniNx+T</td>
<td>18 ± 2</td>
</tr>
</tbody>
</table>

F

mRNA expression (relative to 18s) normalized to HFD Sham

<table>
<thead>
<tr>
<th>Gene</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cd11c</td>
<td>1.2 ± 0.2</td>
</tr>
<tr>
<td>IL-6</td>
<td>1.3 ± 0.1</td>
</tr>
<tr>
<td>Tnfα</td>
<td>1.1 ± 0.3</td>
</tr>
<tr>
<td>IL-1β</td>
<td>0.8 ± 0.4</td>
</tr>
<tr>
<td>Hif1α</td>
<td>0.9 ± 0.5</td>
</tr>
<tr>
<td>Cd31</td>
<td>0.7 ± 0.6</td>
</tr>
</tbody>
</table>
**Figure 6**

A. IS GDR (mg/kg·min)

B. Skeletal muscle glucose uptake (mg/kg·min)

C. mRNA expression (relative to 18s) normalized to HFD Sham

- **Cd31**
- **Hif1α**
Supplementary Figure 1

Similar respiratory quotient, locomotor activity and food intake in HFD-fed sham-operated and UniNx mice

(A and B) Respiratory quotient (RQ) and activity was determined in metabolic cages in HFD-fed sham-operated (black symbols) and UniNx (grey symbols) mice. (C) Food intake was measured in metabolic cages in HFD-fed sham-operated (black bars) and UniNx (grey bars) mice. n=7-8. Error bars represent SEM.
C

![Graph showing food intake comparison between Sham and UniNx groups.](image)

- **Food intake (g)**
- **Sham**
- **UniNx**
Supplementary Figure 2

Blood glucose concentrations and glucose infusion rates during hyperinsulinemic-euglycemic clamp

(A) Blood glucose levels were clamped upon insulin infusion at about 5 mmol/l in HFD-fed sham (black symbols) and UniNx (grey symbols) mice. n=5. (B) In order to maintain euglycemia, glucose infusion rate was adjusted over time. n=5.
Supplementary Figure 3

Similar CD31 and HIF1α mRNA expression in chow-fed sham-operated and UniNx mice

mRNA expression of CD31 and HIF1α in quadriceps muscle of chow-fed sham-operated (black bars) and UniNx mice (grey bars). n=5.
Supplementary Figure 4

Blood glucose concentrations and glucose infusion rates during hyperinsulinemic-euglycemic clamp in telmisartan-treated HFD-fed mice

(A) Blood glucose levels were clamped upon insulin infusion at about 5 mmol/l in telmisartan-treated HFD-fed sham (black circles) and UniNx (grey circles) mice. n=5.

(B) In order to maintain euglycemia, glucose infusion rate was adjusted over time. n=5.